ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

2021 - How Commercial Insights Can be Used to Maximize an Early Exit



VenueXtalks, Canada Canada

KeywordsBiopharmaceutical; Product Development; Commercial Insights


Topics/Call fo Papers

Out-licensing or selling an asset prior to the initiation of pivotal Phase III studies or an NDA submission is always challenging. However, the likelihood of effecting an attractive exit can be significantly enhanced through proactive, strategic planning and the use of commercial insights. To realize an early exit before Phase III or NDA submission, it is critical that sponsors understand the out-licensing environment and develop a cohesive commercial strategy that articulates how the success of the product can be maximized.
This webinar will provide an overview of the commercial insights that should be gathered in the early phases of development and will provide guidance on best practices to use these insights to:
Focus and drive the development process,
Identify the right type of commercial partners, and
Enhance the ability to negotiate better terms for an exit or out-licensing deal.

Last modified: 2021-07-28 19:28:53